Task V32: MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE 1 AND 2
Task V32: MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE 1 AND 2
批准号:
10938084
负责人:
SUNEEL SINGH
金额:
$261.71万
依托单位:
--
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-26 至 2024-09-25
关键词:
AdjuvantBiological ProductsBioterrorismClinical ResearchCommunicable DiseasesContractsCyclic GMPDevelopmentDevelopment PlansEmerging Communicable DiseasesHumanPhaseServicesSystemUnited States Food and Drug AdministrationVaccinesinfluenzavirusmanufacturenovel vaccinesproduct developmentuniversal influenza vaccinevaccine deliveryvaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and feasibility assessments; product optimization; product development and cGMP compliant manufacture for Phase I/II clinical studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism and emerging and re-emerging infectious diseases. This contract also provides for manufacture of vaccines, vaccine components including adjuvants, vaccine delivery systems, other biologics, and challenge material.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金